Omalizumab Benefits Patients With Chronic Inducible Urticaria Omalizumab Benefits Patients With Chronic Inducible Urticaria

The recombinant anti-immunoglobulin E (IgE) monoclonal antibody omalizumab has ' substantial benefits ' in treating various forms of chronic inducible urticaria (CIndU), according to a new systematic review.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news